Abstract: The pressure to develop new network architectures and multiple access technologies is driven by increasing demands on network performance, number of devices, network traffic, and use cases.
From this month, the cost of a 10-minute, six-monthly Ocrevus (ocrelizumab) subcutaneous injection for relapsing-remitting multiple sclerosis (MS) will be slashed from more than $16,500 to $31.60 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback